Glenmark Pharmaceuticals Ltd. (GLENMARK) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Part of MojoOne Strategy

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Laurus Labs

Glenmark Pharma

Ipca Labs

Ajanta Pharma

Aurobindo Pharma

Alkem Lab

Biocon

Abbott India

Mankind Pharma

Glaxosmi. Pharma

Anthem Bioscienc

Why is Glenmark Pharmaceuticals Ltd. ?

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.89 times

Positive results in Dec 25

NET SALES(Latest six months) At Rs 9,947.49 cr has Grown at 45.83%
PAT(Latest six months) Higher at Rs 2,026.77 cr
ROCE(HY) Highest at 35.65%

With ROE of 23.5, it has a Attractive valuation with a 5.8 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 39.14%, its profits have risen by 890.4% ; the PEG ratio of the company is 0

High Institutional Holdings at 39.33%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Glenmark Pharma should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Glenmark Pharma for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Glenmark Pharma

39.14%

1.26

31.14%

Sensex

8.49%

0.74

11.41%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.70%

EBIT Growth (5y)

19.50%

EBIT to Interest (avg)

6.97

Debt to EBITDA (avg)

1.60

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

1.06

Tax Ratio

33.64%

Dividend Payout Ratio

6.74%

Pledged Shares

Institutional Holding

39.33%

ROCE (avg)

16.69%

ROE (avg)

10.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.78

EV to EBIT

14.10

EV to EBITDA

12.33

EV to Capital Employed

6.64

EV to Sales

3.27

PEG Ratio

0.03

Dividend Yield

0.26%

ROCE (Latest)

44.14%

ROE (Latest)

23.46%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company

NET SALES(Latest six months)

At Rs 9,947.49 cr has Grown at 45.83%

PAT(Latest six months)

Higher at Rs 2,026.77 cr

ROCE(HY)

Highest at 35.65%

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 2,690.24 cr

DEBT-EQUITY RATIO(HY)

Lowest at 0.13 times

-3What is not working for the Company

PBT LESS OI(Q)

At Rs 673.87 cr has Fallen at -19.3% (vs previous 4Q average

Loading Valuation Snapshot...

Here's what is working for Glenmark Pharma

Profit After Tax (PAT) - Latest six months

At Rs 2,026.77 cr has Grown at 188.64%

Year on Year (YoY)

MOJO Watch

PAT trend is very positive

PAT (Rs Cr)

Net Sales - Latest six months

At Rs 9,947.49 cr has Grown at 45.83%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months

Higher at Rs 2,026.77 cr

than preceding 12 month period ended Dec 2025 of Rs 1,117.42 cr

MOJO Watch

In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Cash and Cash Equivalents - Half Yearly

Highest at Rs 2,690.24 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio - Half Yearly

Lowest at 0.13 times

in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Glenmark Pharma

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 673.87 cr has Fallen at -19.3% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 834.64 Cr

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)